Most patients were satisfied with topical finasteride, and few experienced side effects.
September 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
September 2025 in “International Journal of Women’s Dermatology” Oral spironolactone effectively promotes hair growth in premenopausal women but may cause irregular menstruation.
September 2025 in “JAAD International” Thrice-weekly dutasteride improved hair density and thickness more than twice-weekly, but not hair count compared to daily finasteride.
September 2025 in “The Professional Medical Journal” Oral minoxidil is safe and effective for increasing hair thickness in men with hair loss.
September 2025 in “Clinical Cosmetic and Investigational Dermatology” Kūlaris improved quality of life for acne sufferers without side effects.
September 2025 in “Journal of the American Academy of Dermatology” Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.
August 2025 in “Dermatology Reports” Rosemary oil may reduce hair greying risk.
August 2025 in “Archives of Dermatological Research” Oral minoxidil is more effective than topical minoxidil for hair growth in men.
August 2025 in “Journal of Ayurveda and Integrated Medical Sciences” Combining Ayurvedic and modern treatments can effectively manage hair loss.
August 2025 in “Archives of Dermatological Research” Oral minoxidil may help with pediatric hair disorders but has notable side effects.
The 0.05% dutasteride topical solution effectively promotes hair growth with fewer side effects than oral treatments.
August 2025 in “International Journal of Scientific Research” Oral minoxidil effectively promotes hair growth in men with hair loss, but caution is needed for older or heart-risk patients.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
July 2025 in “Chemistry & Biodiversity” Musa paradisiaca and Musa sapientum have potential health benefits and could be alternatives to synthetic drugs.
July 2025 in “American Journal of Clinical Dermatology” Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.
July 2025 in “International Journal of Dermatology” Safe alopecia treatments for breastfeeding women are limited due to potential risks to infants.
Biosea® Revive Serum is safe and effective for improving hair growth and health.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
June 2025 in “Frontiers in Immunology” Sampling methods greatly affect skin microbiome data in acne studies.
May 2025 in “Journal of Dermatological Treatment” The shampoo improved seborrheic dermatitis symptoms, but worked better for males than females.
May 2025 in “Immunotherapy” Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.
Ongoing monitoring and treatment are crucial to manage sarcoptic mange in reintroduced red foxes.
May 2025 in “Lasers in Surgery and Medicine” Nonablative monopolar radiofrequency is a safe and effective long-term treatment for acne.
Oral betamethasone mini-pulses effectively treat moderate to severe alopecia areata with manageable side effects.
April 2025 in “Nutrients” Consult an oncologist before using supplements for hair loss during breast cancer treatment.
April 2025 in “Advances in Traditional Medicine” Rosemary essential oil spray can effectively increase hair density in alopecia treatment.
March 2025 in “Indian Journal of Dermatology Venereology and Leprology” Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.